We are live on ! Find out more
IMVT icon

Immunovant

118 hedge funds and large institutions have $322M invested in Immunovant in 2021 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 40 increasing their positions, 45 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,952% more call options, than puts

Call options by funds: $22.9M | Put options by funds: $1.12M

10% more capital invested

Capital invested by funds: $293M → $322M (+$28.1M)

3.53% more ownership

Funds ownership: 29.38%32.91% (+3.5%)

5% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 20

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

1% less funds holding

Funds holding: 119118 (-1)

11% less repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 45

Holders
118
Holders Change
-1
Holders Change %
-0.84%
% of All Funds
1.82%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
21
Increased
40
Reduced
45
Closed
20
Calls
$22.9M
Puts
$1.12M
Net Calls
+$21.8M
Net Calls Change
-$22.6M

IMVT Hedge Fund Activity: Q4 2021 in Review

118 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q4 2021, worth a combined $322M — up 9.6% from $293M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new IMVT positions and 20 closed out — a net gain of 1 holder — while 40 added to existing stakes and 45 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $7.43M. The largest seller was State Street, cutting an estimated $11M.

  • 118 institutional investors held Immunovant (IMVT) as of Q4 2021, down from 119 in Q3 2021.
  • Funds reported $322M of Immunovant stock for Q4 2021, up 9.6% quarter-over-quarter.
  • 21 funds opened new Immunovant positions in Q4 2021 and 20 closed out, a net change of +1 holder.
  • The largest Immunovant buyer in Q4 2021 was Point72 Asset Management, an estimated $7.43M added.
  • The largest Immunovant seller in Q4 2021 was State Street, an estimated $11M sold.

Based on aggregated 13F filings for Q4 2021.